Philip Dormitzer

Philip Dormitzer

Pfizer Inc. - New York / United States
Natural Sciences / Biological Science
AD Scientific Index ID: 4375639
-
person_outline Philip Dormitzer's MOST POPULAR ARTICLES
1-) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccineFP Polack, SJ Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, ...New England journal of medicine, 2020103312020
2-) Safety and immunogenicity of two RNA-based Covid-19 vaccine candidatesEE Walsh, RW Frenck Jr, AR Falsey, N Kitchin, J Absalon, A Gurtman, ...New England Journal of Medicine 383 (25), 2439-2450, 202020262020
3-) COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesU Sahin, A Muik, E Derhovanessian, I Vogler, LM Kranz, M Vormehr, ...Nature 586 (7830), 594-599, 202014272020
4-) Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman, S Lockhart, ...Nature 586 (7830), 589-593, 202018072020
5-) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 monthsSJ Thomas, ED Moreira Jr, N Kitchin, J Absalon, A Gurtman, S Lockhart, ...New England Journal of Medicine 385 (19), 1761-1773, 202114702021